Switch theme
Sign up to access all valuation multiples
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
1998
995
LTM Revenue $424M
LTM EBITDA -$31.4M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Glaukos has a last 12-month revenue (LTM) of $424M and a last 12-month EBITDA of -$31.4M.
In the most recent fiscal year, Glaukos achieved revenue of $383M and an EBITDA of -$95.6M.
Glaukos expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Glaukos valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $424M | XXX | $383M | XXX | XXX | XXX |
| Gross Profit | $348M | XXX | $289M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | -$31.4M | XXX | -$95.6M | XXX | XXX | XXX |
| EBITDA Margin | -7% | XXX | -25% | XXX | XXX | XXX |
| EBIT | -$78.2M | XXX | -$108M | XXX | XXX | XXX |
| EBIT Margin | -18% | XXX | -28% | XXX | XXX | XXX |
| Net Profit | -$77.4M | XXX | -$146M | XXX | XXX | XXX |
| Net Margin | -18% | XXX | -38% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Glaukos's stock price is $94.
Glaukos has current market cap of $5.4B, and EV of $5.2B.
See Glaukos trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $5.4B | XXX | XXX | XXX | XXX | $-1.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Glaukos has market cap of $5.4B and EV of $5.2B.
Glaukos's trades at 13.5x EV/Revenue multiple, and -54.3x EV/EBITDA.
Equity research analysts estimate Glaukos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Glaukos has a P/E ratio of -69.6x.
See valuation multiples for Glaukos and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.4B | XXX | $5.4B | XXX | XXX | XXX |
| EV (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV/Revenue | 12.3x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBITDA | -165.5x | XXX | -54.3x | XXX | XXX | XXX |
| EV/EBIT | -66.4x | XXX | -48.0x | XXX | XXX | XXX |
| EV/Gross Profit | 14.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -69.6x | XXX | -36.8x | XXX | XXX | XXX |
| EV/FCF | 23374.9x | XXX | -76.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGlaukos's last 12 month revenue growth is 26%
Glaukos's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Glaukos's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Glaukos's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Glaukos and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | -7% | XXX | -25% | XXX | XXX | XXX |
| EBITDA Growth | -124% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 0% | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 104% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Glaukos acquired XXX companies to date.
Last acquisition by Glaukos was XXXXXXXX, XXXXX XXXXX XXXXXX . Glaukos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Glaukos founded? | Glaukos was founded in 1998. |
| Where is Glaukos headquartered? | Glaukos is headquartered in United States of America. |
| How many employees does Glaukos have? | As of today, Glaukos has 995 employees. |
| Who is the CEO of Glaukos? | Glaukos's CEO is Mr. Thomas W. Burns. |
| Is Glaukos publicy listed? | Yes, Glaukos is a public company listed on NYS. |
| What is the stock symbol of Glaukos? | Glaukos trades under GKOS ticker. |
| When did Glaukos go public? | Glaukos went public in 2015. |
| Who are competitors of Glaukos? | Similar companies to Glaukos include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Glaukos? | Glaukos's current market cap is $5.4B |
| What is the current revenue of Glaukos? | Glaukos's last 12 months revenue is $424M. |
| What is the current revenue growth of Glaukos? | Glaukos revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Glaukos? | Current revenue multiple of Glaukos is 12.3x. |
| Is Glaukos profitable? | Yes, Glaukos is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Glaukos? | Glaukos's last 12 months EBITDA is -$31.4M. |
| What is Glaukos's EBITDA margin? | Glaukos's last 12 months EBITDA margin is -7%. |
| What is the current EV/EBITDA multiple of Glaukos? | Current EBITDA multiple of Glaukos is -165.5x. |
| What is the current FCF of Glaukos? | Glaukos's last 12 months FCF is $0.2M. |
| What is Glaukos's FCF margin? | Glaukos's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Glaukos? | Current FCF multiple of Glaukos is 23374.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
